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Abstract: 
A beta-elimination reaction generally involves the cleavage of a sigma (σ) bond at the position beta (β) to a pair of 
electrons that departs a molecule via a nucleophilic leaving group, subsequently leading to the formation of a new pi (π) 
bond. We describe the importance of β-elimination reactions in the mechanisms of action of two classes of 
chemotherapeutic agents. First, we evaluate the chemical steps resulting in formation of 5-methyl-cytosine and its 
disassociation from DNA methytransferase (DNMT) by -elimination reaction. When carbon 5 (C5) of cytosine is 
substituted with a nitrogen atom (N) in 5-aza-cytosine analogues, the critical β-elimination reaction cannot proceed, which 
results in the permanent attachment of 5-aza-cytosine to DNMT. The net outcome is entrapment of the DNMT by 
5-aza-cytosine analogues and its eventual degradation, leading to DNA hypomethylation. Second, we analyze the critical 
role of β-elimination reaction in the activation of cyclophosphamide and ifosfamide. The incapability of undergoing 
β-elimination results in reduction of the cytotoxic activity of these agents. It appears that the conversion of aldehyde 
group, in aldophosphamide metabolites of cyclophosphamide and ifosfamide, to carboxyl group by aldehyde 
dehydrogenase makes the protons on the carbon atom attached to carboxyl group not acidic enough that can be removed 
under physiologic conditions via initiation of the critical β-elimination reaction. This ultimately culminates in a selective 
cytotoxic effect of these agents against lymphocytes, but not against hematopoietic and other stem cells with high 
aldehyde dehydrogenase content. 
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β-Elimination Reactions 
β-elimination reactions play an integral role in normal physiologic function and in activation of prodrugs into 
active compounds. Both of these scenarios represent key steps that several antineoplastic therapeutic agents 
exploit in order to achieve clinical activity and efficacy. These include, but are not limited to, the 
hypomethylating agents such as azacitidine and decitabine, and the nitrogen-mustard alkylating agents 
cyclophosphamide and ifosfamide. It is thus important to have a basic understanding of the intricacies of 
β-elimination reactions and how they participate in the clinical activity of these agents. 
In organic chemistry, an elimination reaction generally involves the cleavage of a sigma (σ) bond and 
departure of a nucleophilic leaving group, subsequently leading to the formation of a new pi (π) bond (Figure 1) 
[1]. This process is called β-elimination when the σ bond beta (β) to the pair of nucleophilic electrons breaks in 
order to create the new π bond. The formation of the π bond may occur by a one- or two-step process via 
bimolecular or unimolecular elimination, respectively. Unimolecular β-elimination (E1) involves only one 
molecular entity and represents a two-step process in which: (1) a carbocation intermediate is formed after 
dissociation of carbon-nucleophile bond; and (2) the carbocation intermediate is deprotonated. Bimolecular 
β-elimination (E2), on the other hand, involves a one-step process with two molecular entities in which a Lewis 
base with a lone pair of electrons removes one hydrogen (proton) from the alpha carbon (Cα) to form a double 
bond between Cα and the beta carbon (Cβ) while a nucleophile (e.g. halide) simultaneously leaves Cβ (Figure 1) 
[1]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Top: The mechanism of the bimolecular β-elimination reactions (E2). Simultaneously, (1) a lone pair of electrons 
from a Lewis base removes a proton (H) from Cα, (2) the pair of electrons between Cα and H forms a new π bond between Cα 
and Cβ, which (3) promotes the loss of a leaving group (Nu*). Bottom: An E2 β-elimination reaction results in formation of a 
π bond between Cα and Cβ (double bond or alkene) after departure of a sulfide-containing moiety (:S-R). Professional 
illustration by John Ott. 
A specific form of β-elimination is called the Elimination Unimolecular Conjugate Base (E1cB) 
mechanism, which occurs under basic conditions. In an E1cB elimination reaction, there are two steps: (1) an 
acidic proton on the Cα adjacent to a carbonyl group is removed by a base; and (2) the elimination occurs through 
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formation of a carbanion intermediate that is the conjugate base of the original molecule, in which the negative 
charge is stabilized by conjugation (i.e. delocalization of electrons) with a carbonyl group (Figure 2) [1].  
 
 
 
 
Figure 2 An E1cB β-elimination reaction resulting in the formation of acrolein (propenal). Cα is attached to an aldehyde 
(carbonyl group), and the proton attached to Cα is an acidic proton, which can be removed by a base resulting in formation of 
a double bond between Cα and Cβ after departure of an oxide-containing moiety (:O-R). Professional illustration by John Ott. 
β-Elimination in Azacitidine and Decitabine 
Azacitidine and decitabine are DNA methyltransferase inhibitors (DNMTI), which are approved by the United 
States Food and Drug Administration (FDA) for the treatment of patients with myelodysplastic syndrome (MDS) 
[2, 3]. In the last decade, these agents have been widely used as an alternative to the standard cytarabine and 
anthracycline-based chemotherapy for treatment of patients with acute myeloid leukemia (AML) who cannot 
tolerate or have progressed on conventional cytotoxic chemotherapy [4]. A 20-40% overall response rate to 
DNMTIs in patients with AML has been reported with overall survival rates comparable to those seen with 
cytotoxic agents [5-7]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 The chemical structures of cytidine, azacitidine and decitabine showing their similarities and differences. 
 
 
Azacitidine (5-aza-cytidine) and decitabine (5-aza-2'-deoxycytidine) are pyrimidine analogs of cytidine, 
in which the carbon 5 (C5) of cytosine is substituted with a nitrogen atom (N). Nitrogen 5 (N5) forms three bonds 
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with the two carbons in the cytosine pyrimidine ring and, as opposed to C5, is not attached to a hydrogen (Figure 
3).  
The exact mechanism of action of azacitidine and decitabine is not yet fully known. It is believed that 
the main mechanism through which these agents exert their antineoplastic activity is via the inhibition of DNA 
methyltransferases culminating in DNA hypomethylation, particularly in the promoter region of tumor 
suppressor genes [8]. For this reason, these agents are commonly called hypomethylating agents [9]. 
 
  
 
Figure 4 Top: The chemical reactions result in formation of 5-methylcytosine and its release from DNA methyltransferase 
mediated by a β-elimination reaction. Bottom: The mechanism by which 5-aza-cytosine analogues are methylated. Due to the 
absence of the β-elimination reaction they are not released from DNA methyltransferase, resulting in its degradation and 
unavailability for future methylation reactions, which culminates in therapeutic hypomethylation of DNA. Professional 
illustration by John Ott. 
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β-elimination plays an important role in the physiologic process of cytosine methylation mediated by 
DNA methyltransferase (Figure 4). With DNMTIs, the substitution of N5 in place of C5 prevents the occurrence 
of the β-elimination reaction, which results in the permanent attachment of azacitidine or decitabine to the DNA 
methyltransferase enzyme and ultimately to the degradation of the enzyme. After recognition by the DNA 
methyltransferase, cytosine is positioned in the enzyme by hydrogen bonds. The process of methylation on C5 is 
initiated by a nucleophilic attack on C6 by a cysteine residue on the DNA methyltransferase forming a covalent 
bond with the cytosine ring through an addition reaction. Next, the electrons are pushed from the double bond 
between C6 and C5 to form a double bond between C5 and C4 of the cytosine ring, which in turn results in 
protonation of N3 [10]. The reverse flow of electrons results in cleavage of the π bond between C5 and C4 and 
formation of a new σ bond between C5 and a methyl group, which is originated from S-adenosyl-methionine 
(SAM), a universal methyl group donor. 5-methyl-cytosine dissociates from DNA methyltransferase through a 
critical β-elimination reaction which results in the simultaneous removal of a proton, formation of a double bond 
between C6 and C5, and loss of the sulfide-containing leaving group from the DNA methyltransferase [10]. The 
ultimate product is formation of 5-methylcytosine and availability of DNA methyltransferase for future 
methylation reactions (Figure 4, Top). 
When 5-aza-cytosine analogues are used, they are incorporated into the DNA methyltransferase 
enzymes instead of the cytosine. The process of methylation of N5 is very similar to methylation of C5. However, 
due to the lack of a hydrogen (proton) attached to the N5, the critical β-elimination reaction cannot proceed. The 
lack of β-elimination results in the permanent attachment of 5-aza-cytosine to DNA methyltransferase via the 
covalent bond between sulfide and C6. The net outcome is entrapment of the DNA methyltransferase enzyme by 
5-aza-cytosine analogues and its eventual degradation, leading to hypomethylation and achievement of the 
desired antineoplastic effects [11, 12]. 
β-Elimination in Cyclophosphamide and Ifosfamide 
Cyclophosphamide and ifosfamide are nitrogen mustard-based alkylating agents that are used for treatment of 
many solid and hematologic neoplasms (Figure 5) [13, 14]. In contrast to DNMTIs, which exert their therapeutic 
effects via prevention of β-elimination, these agents require β-elimination for their activation. Once activated by 
β-elimination, cyclophosphamide and ifosfamide can create DNA cross-links, interfering with DNA replication 
and leading to cell death. 
Cyclophosphamide and ifosfamide are hydroxylated at C4 in the hepatic microsomal cytochrome P450 
system and are converted to 4-hydroxycyclophosphamide and 4-hydroxyifosfamide, respectively (Figure 6). 
Both of these molecules are in equilibrium with their aldehyde tautomers, aldophosphamide. The protons on Cα 
of aldo tautomers of cyclophosphamide and ifosfomide are acidic enough to promote a base-catalyzed 
β-elimination reaction via the E1cB mechanism (Figure 2) to form active metabolites, phosphoramide mustards 
and the leaving group acrolein. Acrolein, or propenal, is a very reactive α-β unsaturated aldehyde responsible for 
hemorrhagic cystitis after administration of cyclophosphamide or ifosfamide [13]. The phosphoramide mustard 
forms an unstable reactive aziridinium ring, which readily reacts with different nucleophiles (e.g. N7 of a guanine 
base in DNA) forming interstrand and intrastrand crosslinks leading to DNA alkylation and apoptosis of the cells 
 Reddy H et al. American Journal of Cancer Therapy and Pharmacology 2016, 3:1-8 
  
Ivy Union Publishing | http: //www.ivyunion.org September 19, 2016 | Volume 3 Issue 1 
Page 6 of 8 
[13]. 
 
 
 
 
 
 
Figure 5 The chemical structures of cyclophosphamide and ifosfamide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 The mechanism of action activation of cyclophosphamide and ifosfamide underscoring the importance of the E1cB 
β-elimination reaction. Professional illustration by John Ott. 
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The role of the β-elimination reaction is critical in the activation of cyclophosphamide and ifosfamide. 
The inability of undergoing β-elimination results in the lack of cytotoxic activity of these agents. 
Aldophosphamides can be oxidized to carboxyphosphamides by aldehyde dehydrogenases which are found in 
high levels within hematopoietic and other stem cells, but not in mature lymphocytes. The protons on Cα attached 
to carboxyl group are not acidic enough that they can be removed under physiologic conditions via initiation of 
the critical E1cB-mediated β-elimination reaction necessary for activation of these compounds. The conversion 
of aldehyde group to carboxyl group by aldehyde dehydrogenase of stem cells culminates in selective cytotoxic 
effect of cyclophosphamide against lymphocytes but not stem cells. In recent years, administration of high-dose 
cyclophosphamide after allogeneic blood or bone marrow transplantation has resulted in a reduction in the rates 
of graft-versus-host disease (GVHD) by selective removal of alloreactive T cells, but not donor stem cells, which 
in turn has expanded the donor pool for many patients by allowing successful use of human leukocyte antigen 
(HLA)-haploidentical grafts [15]. 
In conclusion, a basic understanding of β-elimination reactions and the central role they play in the 
mechanism of action of the 5-aza-pyrimidine analogues discussed here is imperative to optimize these agents’ 
full potential for clinical efficacy. Further, it is important to appreciate the effect of the fine balance between more 
acidic and less acidic proton on carbons attached to the carbonyl groups of aldehyde versus carboxyl groups for 
initiation of the required E1cB β-elimination reaction for activation of cyclophosphamide and ifosfamide. 
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